Jazz Pharmaceuticals PLC JAZZ
Morningstar’s Analysis
There is no Morningtar’s Analysis data available.
Company Profile
Business Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.
Contact
Waterloo Road, Fifth Floor, Waterloo Exchange
Dublin, D04 E5W7, Ireland
Dublin, D04 E5W7, Ireland
T +353 16347800
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type —
Employees 1,940